Perrigo Co Financial Results
Perrigo reported third quarter 2026 financial results, showing a 5.2% decline in 'All In' net sales to $989 million and a reported diluted loss per share of $0.10. The company updated its full-year outlook to reflect the divestiture of its Infant Formula business and more cautious retailer inventory positioning ahead of the cough and cold season.
- Term
- Q3 2026
“Our Three-S plan is delivering continued progress in the areas of the business within our control. We gained market share again in U.S. store brand OTC and in key European brands. Category trends improved sequentially, which, combined with disciplined cost management, helped offset a difficult consumer backdrop.”
Albert Manzone, Interim President and Chief Executive Officer
“The sale of Infant Formula is an important step in evolving Perrigo into a more focused consumer self-care company. It is expected to enhance our margin profile, materially reduce expected future capital expenditures, and support continued deleveraging and reinvestment in the business. The result will be a simpler Perrigo, better positioned for profitable growth.”
Albert Manzone, Interim President and Chief Executive Officer